Neuropathic pain (NP) affects about 8% of the people in the Western World and the commonest cause is diabetes mellitus. NP places an enormous emotional and financial burden on patients, carers and society. Very few NP patients obtain complete pain relief with the currently available drugs and more effective long-term therapies are urgently required. My basic-science and clinical research is focused on better understanding the mechanisms that underlie the development and maintenance of NP.
Over the last 20 years my group has identified and validated the second galanin receptor (GalR2) as a novel treatment for NP. I am now translating ...
View complete publications list in the University of Bristol publications system
Edit this profile If you are Professor David Wynick, you can edit this page. Login required.
All details on one page > for printing etc.